Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Seiji Niho's publication output changed over time?
ScholarIQpublication output · 2004–2020
Output grew0% over the shown period — from 1 works in 2004 to 1 in 2020.
1
1
1
1
2
1
1
1
1
1
2004200520122013201420162017201820192020
What are the most-cited papers on Seiji Niho?
ScholarIQmost cited works
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi‐Long Wu, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Fumito Tsuji, R. Linke, Rafael Rosell, J. Corral, Maria Rita Migliorino, Adam Płużański, Eric Sbar, Tao Wang, Jane Liang White, Sashi Nadanaciva, Rickard Sandin, Tony Mok
The Lancet Oncology. 20171,219 Citations
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and <i>EGFR</i>-Activating Mutations
Tony Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Min Lee, R. Linke, Rafael Rosell, J. Corral, Maria Rita Migliorino, Adam Płużański, Eric Sbar, Tao Wang, Jane Liang White, Yi‐Long Wu
Journal of Clinical Oncology. 2018439 Citations
Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis
Shigeki Umemura, Sachiyo Mimaki, Hideki Makinoshima, Satoshi Tada, Genichiro Ishii, Hironobu Ohmatsu, Seiji Niho, Kiyotaka Yoh, Shingo Matsumoto, Akiko Takahashi, Masahiro Morise, Yuka Nakamura, Atsushi Ochiai, Kanji Nagai, Reika Iwakawa, Takashi Kohno, Jun Yokota, Yuichiro Ohe, Hiroyasu Esumi, Katsuya Tsuchihara, Kōichi Goto
Journal of Thoracic Oncology. 2014219 CitationsOPEN ACCESS
Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer
Seiji Niho, Hideo Kunitoh, Hiroshi Nokihara, Takeshi Horai, Yukito Ichinose, Toyoaki Hida, Nobuyuki Yamamoto, Masaaki Kawahara, Tetsu Shinkai, Kazuhiko Nakagawa, Kaoru Matsui, Shunichi Negoro, Akira Yokoyama, Shinzoh Kudoh, Katsuyuki Kiura, Kiyoshi Mori, Hiroaki Okamoto, Hiroshi Sakai, Koji Takeda, Soichiro Yokota, Nagahiro Saijo, Masahiro Fukuoka
Lung Cancer. 2012214 CitationsOPEN ACCESS
Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial
Jun Sato, Miyako Satouchi, Shoichi Itoh, Yusuke Okuma, Seiji Niho, Hidenori Mizugaki, Haruyasu Murakami, Yasuhito Fujisaka, Toshiyuki Kozuki, Kenichi Nakamura, Yukari Nagasaka, Mamiko Kawasaki, Tomoaki Yamada, Ryunosuke Machida, Aya Kuchiba, Yuichiro Ohe, Noboru Yamamoto
The Lancet Oncology. 2020214 Citations
Related on ScholarIQ
Dokkyo Medical University
Institution
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Paper
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and <i>EGFR</i>-Activating Mutations
Paper
Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis
Paper
Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer
Paper
Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial
Paper